Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Short-term Investments (2023 - 2025)

Historic Short-term Investments for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $173.7 million.

  • Compass Therapeutics' Short-term Investments rose 7614.73% to $173.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $173.7 million, marking a year-over-year increase of 7614.73%. This contributed to the annual value of $83.2 million for FY2024, which is 3508.77% down from last year.
  • Per Compass Therapeutics' latest filing, its Short-term Investments stood at $173.7 million for Q3 2025, which was up 7614.73% from $78.1 million recorded in Q2 2025.
  • Compass Therapeutics' 5-year Short-term Investments high stood at $173.7 million for Q3 2025, and its period low was $71.6 million during Q1 2025.
  • For the 3-year period, Compass Therapeutics' Short-term Investments averaged around $120.3 million, with its median value being $128.2 million (2023).
  • The largest annual percentage gain for Compass Therapeutics' Short-term Investments in the last 5 years was 7614.73% (2025), contrasted with its biggest fall of 4600.51% (2025).
  • Compass Therapeutics' Short-term Investments (Quarter) stood at $128.2 million in 2023, then crashed by 35.09% to $83.2 million in 2024, then soared by 108.66% to $173.7 million in 2025.
  • Its Short-term Investments was $173.7 million in Q3 2025, compared to $78.1 million in Q2 2025 and $71.6 million in Q1 2025.